Synthetic Genomics, Inc. Hires Robert H. Cutler as General Counsel

La Jolla, CA – March 3, 2016 – Synthetic Genomics, Inc. (SGI), a leader in the field of synthetic biology, announced today that Robert H. (Rob) Cutler is joining its executive team as General Counsel and Corporate Secretary. Rob has 20 years of corporate legal, intellectual property licensing, regulatory compliance, business development and mergers and acquisitions experience, most of which has been spent in the biotech industry in private and public companies and earlier in his career at leading law firms.

Oliver Fetzer, SGI CEO, said “We are pleased to add Rob to our executive team and look forward to advancing SGI’s industry leading synthetic biology platform under his counsel. Rob’s extensive experience in corporate transactions and corporate governance is an ideal fit as SGI accelerates its growth.  Rob’s life science expertise makes him well suited to play an integral part in SGI’s evolution.”

Rob received his Juris Doctor (JD) degree, graduating cum laude from the Brigham Young University J. Reuben Clark Law School. Rob was most recently General Counsel and Corporate Secretary at LifeVantage Corporation from 2011-2015 where he was responsible for all legal, regulatory, and compliance activities, managed all securities filings, and led expansion into multiple foreign jurisdictions. Prior to LifeVantage, Rob was Vice President, Business Development for Somaxon Pharmaceuticals. Rob also served as Associate General Counsel and Senior Director, Business Development at Biogen Idec Inc. from 2001-2010 where he managed business development efforts for the oncology business unit and closed over $1.5 billion in transactions including acquisitions, multi-product collaborations, strategic alliances, product divestitures and research and academic collaborations.  Prior to joining Biogen Idec, Rob spent several years in private law practice with two large full service law firms where he counseled both private and public companies in securities matters, general corporate transactions and mergers and acquisitions.

About Synthetic Genomics

Synthetic Genomics Inc. (SGI), located in La Jolla, CA, is a leader in the fields of synthetic biology and synthetic genomics, advancing genomics to better life. SGI applies its intellectual property in this rapidly evolving field to design and build biological systems solving global sustainability challenges. SGI serves three end markets: research, bioproduction, and applied products. The company’s research offerings, commercialized through its subsidiary SGI-DNA, are revolutionizing science and medicine with next-generation genomic solutions, including the world’s first DNA printer. SGI applies its integrated synthetic biology capabilities to reinvent bio-based production by improving existing production systems and developing novel, optimized production hosts. SGI develops its applied products, typically in partnership with leading global organizations, across a variety of industries including sustainable bio-fuels, sustainable crops, nutritional supplements, vaccines, and transplantable organs.

Media Contact

Ben Chiarelli, VP of Corporate Development and Strategy